DanielGoldsteinMD

Oncology • Atlanta, GA

Physician

Join to view full profile

Are you Dr. Goldstein?

Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.

Gain access to free telehealth tools, such as our "call shielding" and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
You already have 14 invites waiting!
Read the latest clinical news, personalized to your specialty.

Claim this profile

Not you? Find your profile

Office
49 Jesse Hill Jr. Drive
Suite 146
Atlanta, GA 30303
Phone+1 404-778-1351

Summary

Dr. Daniel Goldstein, MD is an oncologist in Atlanta, Georgia. He is currently licensed to practice medicine in Michigan, Pennsylvania, and Louisiana. He is affiliated with Atlanta Veterans Affairs Medical Center.

Education & Training

Emory University School of MedicineFellowship, Hematology and Medical Oncology, 2012 - 2015
Westchester Medical CenterResidency, Internal Medicine, 2008 - 2011

Certifications & Licensure

OH State Medical License 2013 - 2019
NY State Medical License 1993 - 2018
CT State Medical License 2001 - 2017
IL State Medical License 1998 - 2017
MI State Medical License 2016 - 2017
MO State Medical License 1998 - 2017
NJ State Medical License 2014 - 2017
WI State Medical License 2012 - 2017
LA State Medical License 2015 - 2016
MA State Medical License 2013 - 2016
PA State Medical License 2016 - 2016
AL State Medical License 1995 - 2011
Join now to see all

Clinical Trials

Evaluating Length of Treatment With PD-1/PD-L1 Inhibitor in Advanced Solid Tumors Start of enrollment: 2019 Nov 15
Recruiting
Phase 3

Publications & Presentations

PubMed

7 citations
Dose Optimization of Pembrolizumab: Less May Be More.
Mark J. Ratain, Cody J. Peer, William D. Figg, Daniel A. Goldstein
Clinical Pharmacology and Therapeutics. 2021-12-01
2 citations
Factors Associated With Off-Label Oncology Prescriptions: The Role of Cost and Financing in a Universal Healthcare System.
Noa Gordon, Daniel A. Goldstein, Boaz Tadmor, Salomon M. Stemmer, Dan Greenberg
Frontiers in Pharmacology. 2021-10-19
19 citations
A Pharmacokinetic Simulation Analysis of Less Frequent Nivolumab and Pembrolizumab Dosing: Pharmacoeconomic Rationale for Dose De-Escalation.
Cody J. Peer, Brian L. Heiss, Daniel A. Goldstein, Jennifer C. Goodell, William D. Figg
Journal of Clinical Pharmacology. 2021-10-14

Press Mentions

Study in India Could Make Immunotherapy More Affordable WorldwideNovember 22nd, 2022
Did Vinay Prasad Need to Mention the Nazis to Make a Point on the U.S. Pandemic Response?October 8th, 2021
Best Doctors 2016June 7th, 2017